Apoptosis is a fundamental biological process involved in embryogenesis. morphogenesis. tumour regression and organ involution (for a recent review see Wyllie. 1993) . Since apoptosis is a rather scattered phenomenon in intact tissues. alternative in vitro models have been developed in which apoptotic cell death can be induced in a larger fraction of the cell population.
Apoptosis-like cell death has been induced by addition of cAMP or various cytokines or withdrawal of growth factors (for a recent review see Schwartzman & Cidlowski. 1993) . Recently the protein phosphatase inhibitors okadaic acid (OA) and calyculin A have been found to induce apoptosis in different cell types (Boe et al.. 1991 : Ishida et al.. 1992 : Vintermyr et al.. 1993 .
PAI-2 is considered a component of the fibrinolytic pathway. being an efficient inhibitor of tissue-type plasminogen activator and urokinase plasminogen activator (uPA) . It is principally expressed in monocytes macrophages and trophoblasts (Astedt et al.. 1987; Vassalli et al.. 1992) . PAI-2 lacks a normal NH,-terminal signal sequence (Ye et al.. 1987 : Antalis et al.. 1988 and is by facultative translocation present as both a cytosolic Mr 43.000 and a secreted M, 60.000-70.000 glycoprotein (Belin et al.. 1989) . No intracellular function for the cytosolic PAI-2 has yet been described. even though it has been shown to be a substrate for the intracellular enzyme tissue transglutaminase (Jensen et al.. 1993 (Jensen et al.. . 1994 ). Yet killing of a fibrosarcoma cell line by tumour necrosis factor (TNF) was inhibited by superexpression of the intracellular form of the senine protease inhibitor, plasminogen activator inhibitor-2 (PAI-2) (Kumar & Baglioni. 1991) . suggesting a possible cytoprotective role as seen in the antiapoptotic action of the oncogene bcl-2 (Henderson et al.. 1991) .
The present study was undertaken to determine whether intracellular PAI-2 is modified or its expression altered during in vitro induced apoptosis-like cell death in human promyelocytic leukaemic NB4 cells (de The et al.. 1990 : Lanotte et al., 1991 . We report the occurrence of a novel low molecular weight PAI-2 isoform (Mr -33.000) with intact uPA-binding affinity in apoptotic NB4 cells. Its expression was independent of de noso macromolecular biosynthesis.
suggesting specific proteolytic processing of cellular PAI-2 during NB4 cell apoptosis. This suggests that proteolytically modified intracellular PAI-2 might serve as a biochemical marker for an apoptosis-associated intracellular proteolytic activity. In an attempt to evaluate the clinical significance of this observation we found the cleaved PAI-2 isoform to be present in leukaemic cells from some patients suffering from acute and chronic myeloid leukaemia (AML, CML). RNAse and 100 g mgl-' proteinase K (enzymes purchased from Boehringer Mannheim, Germany), according to standard protocols (Sambrook et al.. 1989 That the cleavage of the ['IjuPA-PAI-2 complex could be in the uPA rather than in the PAI-2 moiety was carefully addressed in further experiments (Figure 3b) . We used the method of Wun and Reich (1987) , rendering the uPA-PAI-2 complexes labile in the presence of the nucleophilic agent hydroxylamine, thus leaving PAI-2 and uPA with intact molecular size. Thus, if the uPA moiety of the uPA-PAI-2 complexes was intact, the dissociated [1"ULMW-uPA from both high and low molecular weight uPA-PAI-2 complexes should co-migrate during a subsequent reducing SDS-PAGE. As shown in Figure 3b A major task was to test whether the specific cleavage of PAI-2 was an essential event in apoptotic cells or more a secondary event caused by the intrusion of extracellular proteases. Firstly, both normal and apoptotic cells excluded (Medcalf, 1992) . Figure 4 shows a Northern blot of purified total RNA hybridised with a 3'2P-labelled PAI-2 cDNA probe (upper panel). In cells exposed to 100 nmol 1' OA, a transient but several-fold increment of the PAI-2 mRNA expression was induced. Peak expression was noted after 12 h exposure to 100 nmol I`OA (lane 4). The expression of PAI-2 mRNA was very low in control cells (Figure 4, lane 1) . but could be detected upon prolonged exposure of the film (not shown). However, in both normal and OA-induced cells only one PAI-2 transcnrpt and of equal size (1.8 kb) was found, excluding the possibility that a smaller PAI-2 transcript could be induced during apoptosis by OA. In the presence of 316 nmol I' OA the PAI-2 mRNA expression occurred earlier, but remained weaker and was not detected at time points later than 6 h from time of exposure (data not shown). The equal loading of mRNA was ascertained by the nearly constant signal when using a A-actin cDNA probe on the same filter ( Figure   4 . lower panel). OA (100 nmol 1`) caused at the protein level an increase in the amount of active intracellular PAI-2 from 9 h and later ( Figure 3, lanes 5 -7) . The PAI-2 cleavage first became detectable by 12 h with more than 50% of the active PAI-2 cleaved at 24 h. Higher (316 nmol 1`) or lower (10 nmol 1-) concentrations of OA did not result in more of the cleaved PAI-2 form (not shown). Thus. an optimal system for the generation of cleaved PAI-2 and, accordingly. the in vitro apoptosis-associated protease activity is represented by the culture of NB4 cells for 24 h in the presence of l00nmoll I OA.
Materals and methods

Materials
PAI-2 cleavage in mveloid leukaemic bone marrow cells In order to search for potential clinical relevance of the low Mr PAI-2 isoform observed during in vitro apoptosis, we screened different types of human myeloid leukaemia cells. In some cell homogenates of myeloid leukaemic cells isolated from the bone marrow of patients suffering from acute and chronic myeloid leukaemia, the cleaved PAI-2 variant was noticed ( Figure 5 , lane I vs lanes 2-5). The leukaemic cells were viable as judged by trypan blue exclusion before homogenisation. The lack of PAI-2 cleavage in the control monocytes is in agreement with previous studies using this technique (for a review see Vassalli et al.. 1992) . Table I shows the prevalence of PAI-2 cleavage observed among some patients suffering from AML, AMML and CML. The low-Mr PAI-2 isoform was more frequently recognised among the CML patients than among the AML patients.
The number of patient specimens examined so far does not allow complete statistical analysis. (Figure 2b ). Increased migration during reducing SDS-PAGE could be due to restraints to denaturation caused by intramolecular cross-links between glutamine and lysine residues as catalysed by transglutaminase rather than a decreased molecular mass. Transglutaminase activation has indeed be associated with cellular apoptosis (Fesus et al., 1989 ). and we recently showed PAI-2 to be a substrate for transglutaminase (Jensen et al., 1993 (Jensen et al., . 1994 (Jensen et al., 1993 (Jensen et al., . 1994 First, dye binding to proteins in cells (Bruno et al., 1992) or cell extracts (Kaufmann. 1989) (Gerschenson & Rotello, 1992) . Interestingly. we found that the increase in cytosolic cleaved PAI-2 in the presence of 100 nmol 1' OA ( Figure 3 ) was somewhat delayed compared with the expression of PAI-2 mRNA ( Figure  4) . the latter more closely reflecting the initiation of apoptotic morphology (Figure 1 ). Thus PAI-2 cleavage might mirror the macromolecular breakdown exemplified by DNA fragmentation. gross proteolysis (Kaufmann. 1989) and rRNA fragmentation (Houge et al.. 1993) . rather than represent an active regulatory step in apoptosis. Recent enzyme-linked immunosorbent assay studies show that PAI-2 levels in serum (Scherrer et al., 1991) and cell homogenates (Wada et al., 1993) can be used as a marker for myeloid leukaemia and in the differentiation between different stages of the leukaemia. The existence of cleaved PAI-2 in some but not all samples from patients suffering from AML and CML (Table I ) might further assist the subclassification of these leukaemias. The importance of cell death-suppressor genes, e.g. bcl-2, and tumour suppressor genes, e.g. p53, the latter in certain situations acting to induce apoptosis, is well established (for a review see Carson & Ribeiro, 1993) . Thus, as the in vitro observations point to the cleaved PAI-2 isoform as a marker for apoptosis. we have initiated studies on the significance of PAI-2 cleavage in myeloid leukaemia in relation to classical apoptosis markers as well as prognosis and response to chemotherapy.
The specific site of proteolysis in PAI-2 has not yet been determined and could be different in the various leukaemic cells and during in vitro NB4 cell apoptosis. as different proteinases could be involved. Notwithstanding this cautionary note, the discovery of PAI-2 and poly(ADP-ribose) polymerase (Kaufmann et al., 1993) OK, okadaic acid; PAGE, polyacrylamide gel electrophoresis; PAI-2, plasminogen activator inhibitor 2; SDS, sodium dodecyl sulphate; uPA, urokinase plasminogen activator.
